Core Insights - Aura Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision therapies for solid tumors aimed at preserving organ function [3] - The CEO, Elisabet de los Pinos, will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on December 2, 2025 [1] - The company's lead candidate, bel-sar (AU-011), is in late-stage development for early choroidal melanoma and early-stage development for other ocular oncology indications and bladder cancer [3] Company Overview - Aura Biosciences is headquartered in Boston, MA, and aims to grow as an innovative global oncology company that positively transforms patients' lives [3] - The company provides a live webcast of events on its "Investors & Media" page, with replays available for 90 days [2] - Investor relations contact is Alex Dasalla, Head of Investor Relations and Corporate Communications [5]

Core Insights - PennantPark Floating Rate Capital Ltd. reported its financial results for the fourth quarter and fiscal year ended September 30, 2025, highlighting a stable net investment income and a focus on middle-market investments [1][2]. Financial Performance - For the quarter ended September 30, 2025, the company reported net investment income of $27.5 million, or $0.28 per share, compared to $18.0 million, or $0.24 per share, for the same period in 2024 [19][30]. - The total investment income for the year ended September 30, 2025, was $261.4 million, up from $186.4 million in 2024 [17][30]. - The company declared distributions of $0.31 per share for the quarter and $1.23 per share for the year, totaling $30.5 million and $113.9 million, respectively [30]. Portfolio and Investment Activity - As of September 30, 2025, the investment portfolio totaled $2,773.3 million, consisting of $2,513.6 million in first lien secured debt [8][35]. - The weighted average yield on debt investments was 10.2% at quarter-end [2][8]. - The company invested $633.0 million in the quarter and $1,741.3 million for the year, with a focus on middle-market companies [10][12]. Debt and Liquidity - The company had a credit facility of $683.8 million and a regulatory debt-to-equity ratio of 1.66x as of September 30, 2025 [2][26]. - The annualized weighted average cost of debt was 6.8% for the year ended September 30, 2025, down from 8.5% in 2024 [25][26]. - Cash equivalents available for investing were $122.7 million as of September 30, 2025 [26]. Recent Developments - In August 2025, the company formed a joint venture, PennantPark Senior Secured Loan Fund II, LLC, with a commitment of $200 million to invest in middle-market loans [31]. - The company acquired a portfolio of high-quality assets totaling approximately $250 million, projected to enhance Core NII by one to two cents per share quarterly [32]. - Subsequent to the quarter-end, the company sold $118 million of assets to PSSL and $191 million to PSSL II, using the proceeds to reduce its debt-to-equity ratio to 1.41x [33].

Core Viewpoint - Exodus Movement, Inc. has announced a definitive agreement to acquire W3C Corp, which includes Monavate and Baanx, to enhance its payments infrastructure and position itself as a leader in on-chain payments [1][2][3] Acquisition Details - The acquisition is valued at $175 million and will be funded through a combination of cash and financing from a credit facility with Galaxy Digital, secured by the company's Bitcoin holdings [7] - The acquisition is subject to regulatory approvals and customary closing conditions, with an expected closing in 2026 [7] Strategic Implications - The acquisition will allow Exodus to control the end-to-end payments experience, integrating issuing, processing, and regulatory capabilities directly into its product suite [3][4] - By bringing card and payments infrastructure in-house, Exodus aims to reduce reliance on third-party providers and support a wider range of assets, including stablecoins [3][4] Market Context - The demand for stablecoin payments has surged, with volumes increasing by 70% from February to August 2025, primarily driven by B2B transactions [4] - The infrastructure expansion is expected to enhance offerings for enterprise clients, enabling flexible payment solutions and partnerships with major players like MetaMask and Ledger [5][6] Financial Outlook - The acquisition is anticipated to diversify Exodus's revenue streams through interchange, processing, and program fees, contributing to a more predictable earnings base [5] - XO Swap, a service offered by Exodus, accounted for 37% of all exchange provider volume in October 2025, indicating strong market presence [5]

Core Insights - Sana Biotechnology, Inc. is set to present at two investor conferences in December, providing a business overview and updates from CEO Steve Harr [1][5] - The presentations will be accessible via webcast on the company's Investor Relations page, with replays available for 30 days post-conference [2] Company Overview - Sana Biotechnology focuses on creating engineered cells as medicines, aiming to repair and control genes, and replace missing or damaged cells [3] - The company operates in Seattle, WA, Cambridge, MA, and South San Francisco, CA, with a vision to make therapies broadly available to patients [3]

Core Insights - PennantPark Investment Corporation reported its financial results for the fourth quarter and fiscal year ended September 30, 2025, highlighting a decrease in net investment income and net asset value per share compared to the previous year [1][19][23]. Financial Performance - For the year ended September 30, 2025, the company had a net investment income of $46.1 million, or $0.71 per share, down from $60.1 million, or $0.92 per share in the previous year, reflecting a decrease of approximately 23% [19][23]. - The net asset value per share decreased to $7.11 from $7.56, representing a decline of 5.9% [2][32]. - Total investment income for the year was $122.4 million, down from $143.8 million in the prior year [16][35]. Portfolio and Investment Activity - As of September 30, 2025, the investment portfolio totaled $1,287.3 million, with 45% in first lien secured debt and 28% in preferred and common equity [2][6]. - The company made purchases of investments totaling $746.6 million for the year, while sales and repayments amounted to $810.4 million [2][8]. - The weighted average yield on debt investments was 11.0% for the year [2][6]. Expenses and Liabilities - Total expenses for the year were $76.3 million, a decrease from $83.7 million in the previous year, primarily due to lower interest expenses [17][19]. - The company had outstanding borrowings of $426.5 million under the Truist Credit Facility as of September 30, 2025, with a weighted average interest rate of 6.5% [25][26]. Distributions - During the year ended September 30, 2025, the company declared total distributions of $62.7 million, or $0.96 per share, compared to $57.4 million, or $0.88 per share in the previous year [29]. Market Position and Strategy - The company maintains a focus on the core middle market, which is characterized by attractive credit spreads and lower leverage, aiming to support net investment income through realizations of equity holdings [5][37].

Core Insights - Brilliant Earth Group, Inc. is a global leader in ethically sourced fine jewelry and will participate in upcoming investor events [1][2][3] Group 1: Upcoming Investor Events - On December 3, 2025, the Company will participate in NobleCon21, hosting a presentation at 1:00pm ET and holding investor meetings throughout the day [2] - On December 11, 2025, the Company will participate in the KeyBanc Capital Markets Consumer Conference virtually, with a fireside chat at 11:15am ET and additional investor meetings [3] Group 2: Company Overview - Brilliant Earth was founded in 2005 with a mission to create a more transparent, sustainable, and compassionate jewelry industry [4] - The Company reported full year Net Sales of $422 million for 2024 and has achieved positive Adjusted EBITDA for 17 consecutive quarters since going public in 2021 [4] - Brilliant Earth operates 42 showrooms across the United States and serves customers in over 50 countries worldwide [4]

Core Points - Lavoro Limited received a notice of non-compliance from Nasdaq due to delayed filing of its Form 20-F for the year ended June 30, 2025 [1][2] - The company is required to submit a plan by November 28, 2025, to regain compliance with Nasdaq's listing rules [3][4] - The delay in filing is attributed to complexities associated with the EJ Plan announced in June 2025 [2] Company Overview - Lavoro is Brazil's largest agricultural inputs retailer and a leading producer of agricultural biological products [5] - The company operates across Latin America, including Brazil, Colombia, Uruguay, and Ecuador, and empowers small and medium-sized farmers with emerging agricultural technologies [5]

ARLINGTON, Va., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Fluence Energy, Inc. (Nasdaq: FLNC) (“Fluence” or the “Company”), a global market leader delivering intelligent energy storage, operational services, and asset optimization software, today announced its results for the three months and full fiscal year ended September 30, 2025. Fiscal Year 2025 Financial Highlights Revenue of $2.3 billion for fiscal year 2025 and $1.0 billion for the fourth quarter, compared to $2.7 billion and $1.2 billion from the same ...

Core Viewpoint - Oxford Industries, Inc. plans to release its third quarter fiscal 2025 financial results on December 10, 2025, after market close, followed by a conference call to discuss the results [1]. Company Information - Oxford Industries is a leader in the apparel industry, owning and marketing several distinctive brands including Tommy Bahama®, Lilly Pulitzer®, Johnny Was®, Southern Tide®, The Beaufort Bonnet Company®, Duck Head®, and Jack Rogers® [3]. - The company's stock has been traded on the New York Stock Exchange since 1964 under the symbol OXM [3]. Conference Call Details - The conference call will be hosted by Thomas C. Chubb III, Chairman, CEO, and President, and K. Scott Grassmyer, Executive Vice President, CFO, and COO, starting at 4:30 p.m. ET [1]. - A live webcast of the conference call will be available on the company's website, with a replay accessible until December 24, 2025 [2].

Core Insights - Rani Therapeutics is participating in the Evercore Healthcare Conference on December 3, 2025, with CEO Talat Imran and CFO Svai Sanford presenting [1] - The company focuses on oral delivery of biologics and drugs, aiming to replace traditional injection methods with its proprietary RaniPill capsule technology [2] Company Overview - Rani Therapeutics is a clinical-stage biotherapeutics company dedicated to advancing technologies for orally administered biologics and drugs [2] - The RaniPill capsule is a novel, proprietary, and patented platform technology designed to facilitate oral dosing instead of subcutaneous or intravenous methods [2] - The company has successfully conducted multiple preclinical and clinical studies to assess the safety, tolerability, and bioavailability of the RaniPill capsule technology [2]